Florentina Simona-Maria Tatarusanu, F. Lupașcu, L. Herciu, I. Vasincu
Usually gastrointestinal discomfort is a very common complaint and most of the time it’s easy to manage in daily pharmaceutical practice. But some conditions can lead to further complications or become worse over time, so it’s really important that patients can access advice and support when they need it. Pharmacists are in the position to guide the selection of the best treatment by confirming the diagnosis, sending patients with alarm symptoms to physicians and educating patients on the proper use of their OTC medication. Gastrointestinal symptoms such as diarrhea and nausea/vomiting are often recognized among the patients with COVID-19. The impact of pharmacist intervention is needed in order to ensure reliable information for preventing, detecting, treating and managing coronavirus infection.
{"title":"Gastrointestinal symptoms from theoretical knowledge to pharmaceutical approach during COVID-19 pandemic","authors":"Florentina Simona-Maria Tatarusanu, F. Lupașcu, L. Herciu, I. Vasincu","doi":"10.37897/rjphp.2021.s.2","DOIUrl":"https://doi.org/10.37897/rjphp.2021.s.2","url":null,"abstract":"Usually gastrointestinal discomfort is a very common complaint and most of the time it’s easy to manage in daily pharmaceutical practice. But some conditions can lead to further complications or become worse over time, so it’s really important that patients can access advice and support when they need it. Pharmacists are in the position to guide the selection of the best treatment by confirming the diagnosis, sending patients with alarm symptoms to physicians and educating patients on the proper use of their OTC medication. Gastrointestinal symptoms such as diarrhea and nausea/vomiting are often recognized among the patients with COVID-19. The impact of pharmacist intervention is needed in order to ensure reliable information for preventing, detecting, treating and managing coronavirus infection.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44626440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The purpose of this research was to apply near-infrared (NIR) spectroscopy in combination with chemometrics to predict particle size and flow characteristics of a meloxicam powder blends for tableting. In order to develop calibration models for particle size (mean particle size, poly-dispersion index), and flow properties (angle of repose and time of flow) prediction, the NIR reflection spectra of different meloxicam powder blends prepared according to an experimental design were analyzed using different preprocessing methods by partial last-square (PLS) regression followed by leaveone-out cross-validation. Very good prediction ability was found for mean particle size, poly-dispersion index, angle of repose, and time of flow in models in whose development no preprocessing spectrum was applied. Also, a good prediction was found preprocessing spectrum such smoothing - moving average for particle size characteristics, and unit vector normalization for powder flow properties. Therefore, NIR-chemometric methods developed in this work can be useful for the prediction of the granulometric properties and parameters related to the flowability of the meloxicam powder blends and may be used as process analytical technology (PAT) tools for process control during meloxicam tablets manufacturing.
{"title":"Prediction of the particle size and flow characteristics of powder blends for tableting by near-infrared spectroscopy and chemometrics","authors":"R. Iovanov, A. Vonica, I. Tomuță","doi":"10.37897/RJPHP.2021.1.3","DOIUrl":"https://doi.org/10.37897/RJPHP.2021.1.3","url":null,"abstract":"The purpose of this research was to apply near-infrared (NIR) spectroscopy in combination with chemometrics to predict particle size and flow characteristics of a meloxicam powder blends for tableting. In order to develop calibration models for particle size (mean particle size, poly-dispersion index), and flow properties (angle of repose and time of flow) prediction, the NIR reflection spectra of different meloxicam powder blends prepared according to an experimental design were analyzed using different preprocessing methods by partial last-square (PLS) regression followed by leaveone-out cross-validation. Very good prediction ability was found for mean particle size, poly-dispersion index, angle of repose, and time of flow in models in whose development no preprocessing spectrum was applied. Also, a good prediction was found preprocessing spectrum such smoothing - moving average for particle size characteristics, and unit vector normalization for powder flow properties. Therefore, NIR-chemometric methods developed in this work can be useful for the prediction of the granulometric properties and parameters related to the flowability of the meloxicam powder blends and may be used as process analytical technology (PAT) tools for process control during meloxicam tablets manufacturing.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42927880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives. The objective of this study was to investigate the possibility of developing metoprolol extended-release tablets by using hydroxypropyl methylcellulose (HPMC) in order to obtain the hydrophilic matrix and Eudragit NE 40D, Kollicoat SR 30D and Surelease E7 as binders during the granulation process. Material and methods. The extended-release tablets were prepared via fluid bed granulation of metoprolol powder using Eudragit NE 40D / Kollicoat SR 30D / Surelease E7 as binders, followed by compression. The influence of three formulation factors (the type of granulation polymers, the ratio of granulation polymers and the HPMC ratio) on the kinetic metoprolol tartrate release was investigated through a full factorial experimental design. Outcomes. The kinetic release of all 26 formulations was best fitted with Peppas model. According to n values of Peppas equation, the release mechanism of drug consists in water diffusion into the matrix, followed by matrix swelling and erosion. The results also indicated that the formulations containing an increased amount of Eudragit NE (10% or more) as binder in the granulation process presented a satisfactory release rate of metoprolol over 12 hours from the granules incorporated in the hydrophilic matrix. Conclusions. This study demonstrated the possibility of lowering of the burst effect from hydrophilic matrix extendedrelease dosage forms incorporating a freely soluble drug, by granulating the drug with a high amount of Eudragit NE 40D and processing the obtained granules in a hydrophilic matrix by tableting.
目标。研究了羟丙基甲基纤维素(HPMC)制备美托洛尔缓释片的可行性，在造粒过程中制备亲水性基质，以Eudragit NE 40D、Kollicoat SR 30D和Surelease E7为粘结剂。材料和方法。以Eudragit NE 40D / Kollicoat SR 30D / surelee7为粘结剂，采用流化床造粒法制备美托洛尔缓释片。采用全因子试验设计，考察了造粒聚合物类型、造粒聚合物比和HPMC比3个配方因素对酒石酸美托洛尔释放动力学的影响。结果。26个剂型的动力学释放均符合Peppas模型。根据Peppas方程的n值，药物的释放机制是水扩散到基质中，然后是基质溶胀和侵蚀。结果还表明，在造粒过程中添加10%或更多的乌龙茶烯(Eudragit NE)作为粘合剂的配方，在亲水性基质中掺入的颗粒中，美托洛尔在12小时内的释放率令人满意。结论。本研究证明了在含有自由溶性药物的亲水基质缓释剂型中，通过将大量的eudrragit ne40d制成颗粒，并通过片剂在亲水基质中处理获得的颗粒，从而降低爆发效应的可能性。
{"title":"Water insoluble polymers as efficient binder in fluid bed granulation of metoprolol for preparation hydrophilic matrix extendedrelease tablets","authors":"D. Hales, C. Pharmacy, C. Alecu, I. Tomuță","doi":"10.37897/RJPHP.2020.4.4","DOIUrl":"https://doi.org/10.37897/RJPHP.2020.4.4","url":null,"abstract":"Objectives. The objective of this study was to investigate the possibility of developing metoprolol extended-release tablets by using hydroxypropyl methylcellulose (HPMC) in order to obtain the hydrophilic matrix and Eudragit NE 40D, Kollicoat SR 30D and Surelease E7 as binders during the granulation process. Material and methods. The extended-release tablets were prepared via fluid bed granulation of metoprolol powder using Eudragit NE 40D / Kollicoat SR 30D / Surelease E7 as binders, followed by compression. The influence of three formulation factors (the type of granulation polymers, the ratio of granulation polymers and the HPMC ratio) on the kinetic metoprolol tartrate release was investigated through a full factorial experimental design. Outcomes. The kinetic release of all 26 formulations was best fitted with Peppas model. According to n values of Peppas equation, the release mechanism of drug consists in water diffusion into the matrix, followed by matrix swelling and erosion. The results also indicated that the formulations containing an increased amount of Eudragit NE (10% or more) as binder in the granulation process presented a satisfactory release rate of metoprolol over 12 hours from the granules incorporated in the hydrophilic matrix. Conclusions. This study demonstrated the possibility of lowering of the burst effect from hydrophilic matrix extendedrelease dosage forms incorporating a freely soluble drug, by granulating the drug with a high amount of Eudragit NE 40D and processing the obtained granules in a hydrophilic matrix by tableting.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41571014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adriana Aurelia Chiș, I. Crăciun, C. Dobrea, F. Gligor, A. Bărbat, L. Rus, Sibiu Romania Polisano Pharmaceuticals Sa
Mesalamine, 5-aminosalicylic acid or mesalazine is the standard therapy of inflammatory bowel disease. A small number of pharmaceutical dosage forms with mesalazine are on the market. The aim of this study was preformulation and preliminary formulation studies of oral gastro-resistant tablets containing 500 mg mesalazine. The reasons why a gastro-resistant tablet was chosen are: increased compliance of the patient, increased chemical stability and modified release modulation (mesalazine has a local effect on mucosa). The raw materials were of pharmaceutical grade. The following analytical techniques were involved: differential scanning chromatography (DCS), in vitro release, particle size determination, high performance liquid chromatography (HPLC). The compatibility of mesalazine with several excipients was tested using DSC. Wet granulation of mesalazine and starch showed that the fourth (LM04) formulation generates the highest amount (69.1%) of granules in the range of 1000–300 μm. Oblong tablets (pilot batches) were produced. The cores were coated with an enteric coating acrylic agent in order to achieve gastro-resistance. A new gastro-resistant tablets mesalazine formulation was developed by means of wet granulation, tableting (oblong tablets) and coating.
{"title":"Preformulation and preliminary formulation studies of mesalazine gastro-resistant tablets","authors":"Adriana Aurelia Chiș, I. Crăciun, C. Dobrea, F. Gligor, A. Bărbat, L. Rus, Sibiu Romania Polisano Pharmaceuticals Sa","doi":"10.37897/RJPHP.2020.4.5","DOIUrl":"https://doi.org/10.37897/RJPHP.2020.4.5","url":null,"abstract":"Mesalamine, 5-aminosalicylic acid or mesalazine is the standard therapy of inflammatory bowel disease. A small number of pharmaceutical dosage forms with mesalazine are on the market. The aim of this study was preformulation and preliminary formulation studies of oral gastro-resistant tablets containing 500 mg mesalazine. The reasons why a gastro-resistant tablet was chosen are: increased compliance of the patient, increased chemical stability and modified release modulation (mesalazine has a local effect on mucosa). The raw materials were of pharmaceutical grade. The following analytical techniques were involved: differential scanning chromatography (DCS), in vitro release, particle size determination, high performance liquid chromatography (HPLC). The compatibility of mesalazine with several excipients was tested using DSC. Wet granulation of mesalazine and starch showed that the fourth (LM04) formulation generates the highest amount (69.1%) of granules in the range of 1000–300 μm. Oblong tablets (pilot batches) were produced. The cores were coated with an enteric coating acrylic agent in order to achieve gastro-resistance. A new gastro-resistant tablets mesalazine formulation was developed by means of wet granulation, tableting (oblong tablets) and coating.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44184751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives. The aim of this study was to evaluate the stability over time after storage under normal environmental thermo-hygrometric conditions of immediate release foaming vaginal tablets. Material and methods. 15 formulation of foaming vaginal tablets prepared according with a Box-Bhenken experimental design were packaged in tightly sealed bottles with anhydrous sodium sulphate as desiccant and stored in normal thermo-hygrometric conditions (temperature of 25°C, relative humidity 40-75%). Immediate after preparation, after 1 and 3 months the tablets pharmaceutical characteristics were analysed and modification over time evaluated. Outcomes. The formulation factors studied with experimental design have, in general, the same influence on tablets characteristics after 1 or 3 months storage as immediate after preparation After one month storage in normal thermohygrometric conditions, an increase of the tablets hardness and the foaming time was observed, and a decrease of the volume of the foam, the mass of carbon dioxide released by the foaming. These modifications are accentuated especially by an increased effervescent mixture ratio and not significantly influenced by the other formulation variables. The results obtained after three months storage show that the changes on the tablets characteristics become slower than in the first month. The tablets hardness reaches maximum values after one month, but also there are slower changes regarding the maximum volume of the foam, the resistance of the foam, or the mass of carbon dioxide released after foaming. Low modification was observed for the pH generated in the water, which has a fairly high stability over time, both at one month and after three months storage. Conclusions. Foaming vaginal tablets stored in normal thermo-hygrometric conditions, suffer a sudden modification of their characteristics during the first month of storage, a phenomenon that is due to both the humidity of the environment and the preparation conditions. This modification can be minimized by preparing and storing tablets in low humidity conditions (lower that 10%) or by preparation the formulations with a low effervescent mixture ratio (less than 25%).
{"title":"Development of fast release foaming vaginal tablets with clotrimazole. II. The influence of the environmental conditions on preparation and stability","authors":"E. László, R. Cluj-Napoca, I. Tomuță, S. Leucuta","doi":"10.37897/RJPHP.2020.4.6","DOIUrl":"https://doi.org/10.37897/RJPHP.2020.4.6","url":null,"abstract":"Objectives. The aim of this study was to evaluate the stability over time after storage under normal environmental thermo-hygrometric conditions of immediate release foaming vaginal tablets. Material and methods. 15 formulation of foaming vaginal tablets prepared according with a Box-Bhenken experimental design were packaged in tightly sealed bottles with anhydrous sodium sulphate as desiccant and stored in normal thermo-hygrometric conditions (temperature of 25°C, relative humidity 40-75%). Immediate after preparation, after 1 and 3 months the tablets pharmaceutical characteristics were analysed and modification over time evaluated. Outcomes. The formulation factors studied with experimental design have, in general, the same influence on tablets characteristics after 1 or 3 months storage as immediate after preparation After one month storage in normal thermohygrometric conditions, an increase of the tablets hardness and the foaming time was observed, and a decrease of the volume of the foam, the mass of carbon dioxide released by the foaming. These modifications are accentuated especially by an increased effervescent mixture ratio and not significantly influenced by the other formulation variables. The results obtained after three months storage show that the changes on the tablets characteristics become slower than in the first month. The tablets hardness reaches maximum values after one month, but also there are slower changes regarding the maximum volume of the foam, the resistance of the foam, or the mass of carbon dioxide released after foaming. Low modification was observed for the pH generated in the water, which has a fairly high stability over time, both at one month and after three months storage. Conclusions. Foaming vaginal tablets stored in normal thermo-hygrometric conditions, suffer a sudden modification of their characteristics during the first month of storage, a phenomenon that is due to both the humidity of the environment and the preparation conditions. This modification can be minimized by preparing and storing tablets in low humidity conditions (lower that 10%) or by preparation the formulations with a low effervescent mixture ratio (less than 25%).","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47584809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Antonoaea, N. Todoran, E. Rédai, R. Vlad, M. Bîrsan, Aura Rusu, A. Ciurba, I. Pharmacy
The pharmacist from the community pharmacy plays a key role in the case of patients who seek directly for pathologies related to pain. Being a health specialist, he has the ability to offer pharmaceutical healthcare for drugs that need a medical prescription and also for the ones that are registered as OTC’s. Ibuprofen (IBU) is a part of the drug group called nonsteroidal anti-inflammatory drugs (NSAIDs) being registered in Romania under 17 pharmaceutical formulation by the National Agency of Drugs and Medical Devices. Due to its pharmacological profile which consists of a low risk of gastro intestinal side effects, IBU is an OTC recommended and frequently prescribed for decreasing the low and moderate pain. World Health Organization (WHO) indicates IBU as a drug that can be used to babies aged over three months. Through this paper, we try to analyze the pharmacist’s vision from the community pharmacy in IBU recommendation. In this paper were mentioned some legal aspects that are linked to the pharmacist competences, and also its approach regarding IBU recommendation during pregnancy and breastfeeding and also to children and to a category of patients who have various associated pathologies.
社区药房的药剂师在直接寻求疼痛相关病理的患者中起着关键作用。作为一名健康专家，他有能力为需要医疗处方的药物以及注册为OTC的药物提供药物保健。布洛芬(IBU)是罗马尼亚国家药品和医疗器械管理局(National Agency of drugs and Medical Devices)在17种药物配方下注册的非甾体类抗炎药(NSAIDs)的一部分。由于其药理特征包括低风险的胃肠道副作用，IBU是一种推荐的非处方药，经常用于减少轻度和中度疼痛。世界卫生组织(WHO)指出，IBU是3个月以上婴儿可以使用的药物。通过本文，我们试图从社区药房在IBU推荐中分析药师的愿景。在本文中提到了一些与药剂师能力相关的法律方面，以及在怀孕和哺乳期间以及对儿童和具有各种相关病理的患者推荐IBU的方法。
{"title":"Ibuprofen in the current practice of the pharmacist in the community pharmacy","authors":"P. Antonoaea, N. Todoran, E. Rédai, R. Vlad, M. Bîrsan, Aura Rusu, A. Ciurba, I. Pharmacy","doi":"10.37897/RJPHP.2020.3.1","DOIUrl":"https://doi.org/10.37897/RJPHP.2020.3.1","url":null,"abstract":"The pharmacist from the community pharmacy plays a key role in the case of patients who seek directly for pathologies related to pain. Being a health specialist, he has the ability to offer pharmaceutical healthcare for drugs that need a medical prescription and also for the ones that are registered as OTC’s. Ibuprofen (IBU) is a part of the drug group called nonsteroidal anti-inflammatory drugs (NSAIDs) being registered in Romania under 17 pharmaceutical formulation by the National Agency of Drugs and Medical Devices. Due to its pharmacological profile which consists of a low risk of gastro intestinal side effects, IBU is an OTC recommended and frequently prescribed for decreasing the low and moderate pain. World Health Organization (WHO) indicates IBU as a drug that can be used to babies aged over three months. Through this paper, we try to analyze the pharmacist’s vision from the community pharmacy in IBU recommendation. In this paper were mentioned some legal aspects that are linked to the pharmacist competences, and also its approach regarding IBU recommendation during pregnancy and breastfeeding and also to children and to a category of patients who have various associated pathologies.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46294779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives. The aim of this study was to optimize the formulation of certain immediate release foaming vaginal tablets, with fast vaginal disintegration (part I), fallowing their time stability (part II). Material and methods. Modde optimizing software and a Box-Bhenken experimental design was used to establish an optimal formula that would provide maximum “in vitro” behaviour advantages, including stability during preservation; and the improvement of the foaming effect. There were prepared 15 formulations of foaming vaginal tablets in order to choose the optimal formula. Outcomes. The main factor, with influence over all the studied parameters, is the percentage of the effervescent mixture in the formulation. The excess of citric acid has a main role in the assurance of local pH; in the improvement of the flowing properties of the powder mixtures before compression; and in the improvement of the effervescent process, having, on the other hand, an effect of decreasing the stability of tablets and increasing their humidity adsorption. Sodium lauryl sulphate, at the chosen concentration levels (0.5-1.5%), did not influence the dependent variables, it only produced a strong-er resistance of the foam. The optimal formula of a foaming vaginal tablet with an optimal stability during preservation must contain 0.5% sodium lauryl sulphate, while the effervescent mixture must contain a percentage of 24% excess of citric acid, and it must represent 44% of the total amount of excipients. Conclusions. The experimental determinations of the optimal formula were close to the theoretical values predicted by the program, this certifying the validity of the optimization and the conclusion draw after analysis the experimental design.
{"title":"Development of foaming vaginal tablets with clotrimazole. Part I. Optimization of the formulation using design of experiments approach","authors":"E. László, C. Pharmacy, I. Tomuță, S. Leucuta","doi":"10.37897/rjphp.2020.2.5","DOIUrl":"https://doi.org/10.37897/rjphp.2020.2.5","url":null,"abstract":"Objectives. The aim of this study was to optimize the formulation of certain immediate release foaming vaginal tablets, with fast vaginal disintegration (part I), fallowing their time stability (part II). Material and methods. Modde optimizing software and a Box-Bhenken experimental design was used to establish an optimal formula that would provide maximum “in vitro” behaviour advantages, including stability during preservation; and the improvement of the foaming effect. There were prepared 15 formulations of foaming vaginal tablets in order to choose the optimal formula. Outcomes. The main factor, with influence over all the studied parameters, is the percentage of the effervescent mixture in the formulation. The excess of citric acid has a main role in the assurance of local pH; in the improvement of the flowing properties of the powder mixtures before compression; and in the improvement of the effervescent process, having, on the other hand, an effect of decreasing the stability of tablets and increasing their humidity adsorption. Sodium lauryl sulphate, at the chosen concentration levels (0.5-1.5%), did not influence the dependent variables, it only produced a strong-er resistance of the foam. The optimal formula of a foaming vaginal tablet with an optimal stability during preservation must contain 0.5% sodium lauryl sulphate, while the effervescent mixture must contain a percentage of 24% excess of citric acid, and it must represent 44% of the total amount of excipients. Conclusions. The experimental determinations of the optimal formula were close to the theoretical values predicted by the program, this certifying the validity of the optimization and the conclusion draw after analysis the experimental design.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41723243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Sylvester, C. Pharmacy, Alina Porfire, M. Achim, I. Tomuță
Objectives. The aim of this study was to develop and validate a NIR-chemometric method for direct quantification of loratadine in powder blends for tableting and tablets, without any sample preparation. Material and methods. Calibration samples were prepared according to an experimental design with 1 variable and 5 level, containing from 8 to 12 mg loratadine/tablet. Outcomes. For the powder blends, the model generated with the use of spectral range 9,000-4,000 cm-1 and FD+SNV pre-treatment method had the best results, considering the number of PLS factors 9, R2 = 0.984 and RMSECV = 0.267%. For the tablets, the model using the spectral range 11,100-7,128 cm-1 and mMN pre-treatment method had the best results, considering the number of PLS factors 10, R2 = 0.985 and RMSECV = 0.170 mg. Using these calibration models, the method was fully validated according to the ICH guidance. For both powder blends and tablets, the best accuracy was obtained at the concentration level of 10 mg/tablet and the relative bias had values between 0.05% and 1.98% respectively -0.360% and 0.618%. Conclusions. The NIR-chemometric method has good reproducibility and satisfactory accuracy and linearity profiles, indicating that this method could be used for direct determination of loratadine in powder blends for tableting and tablets, without any sample preparation.
{"title":"High-throughput NIR-chemometric method for direct quantification of loratadine in powder blends for tableting and tablets","authors":"B. Sylvester, C. Pharmacy, Alina Porfire, M. Achim, I. Tomuță","doi":"10.37897/rjphp.2020.2.4","DOIUrl":"https://doi.org/10.37897/rjphp.2020.2.4","url":null,"abstract":"Objectives. The aim of this study was to develop and validate a NIR-chemometric method for direct quantification of loratadine in powder blends for tableting and tablets, without any sample preparation. Material and methods. Calibration samples were prepared according to an experimental design with 1 variable and 5 level, containing from 8 to 12 mg loratadine/tablet. Outcomes. For the powder blends, the model generated with the use of spectral range 9,000-4,000 cm-1 and FD+SNV pre-treatment method had the best results, considering the number of PLS factors 9, R2 = 0.984 and RMSECV = 0.267%. For the tablets, the model using the spectral range 11,100-7,128 cm-1 and mMN pre-treatment method had the best results, considering the number of PLS factors 10, R2 = 0.985 and RMSECV = 0.170 mg. Using these calibration models, the method was fully validated according to the ICH guidance. For both powder blends and tablets, the best accuracy was obtained at the concentration level of 10 mg/tablet and the relative bias had values between 0.05% and 1.98% respectively -0.360% and 0.618%. Conclusions. The NIR-chemometric method has good reproducibility and satisfactory accuracy and linearity profiles, indicating that this method could be used for direct determination of loratadine in powder blends for tableting and tablets, without any sample preparation.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42360863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Collaboration between health professionals contributes to improving and maintaining a high level of quality of health services. In the first line, the family doctor and the pharmacist have in common the autonomy of organizing their own activity and the fact that they have developed models of collaboration and integration of activities to work together for the benefit of patients. Collaboration between family doctors and pharmacists can be done in working groups, projects, in an organized, struc-tured or informal setting whenever needed. Topics covered include prescribing and issuing medical recipes, avoiding and limiting incidents, side effects and polypharmacy or training the patients, limiting costs and evaluating new drugs. In the Netherlands there is a long tradition and different ways of collaboration between the family doctor and the pharmacist in order to meet the growing and especially changing medical needs of patients.
{"title":"Collaboration between pharmacist and family doctor in the Netherlands","authors":"M. Olăroiu, secretar Soaze","doi":"10.37897/RJPHP.2020.1.3","DOIUrl":"https://doi.org/10.37897/RJPHP.2020.1.3","url":null,"abstract":"Collaboration between health professionals contributes to improving and maintaining a high level of quality of health services. In the first line, the family doctor and the pharmacist have in common the autonomy of organizing their own activity and the fact that they have developed models of collaboration and integration of activities to work together for the benefit of patients. Collaboration between family doctors and pharmacists can be done in working groups, projects, in an organized, struc-tured or informal setting whenever needed. Topics covered include prescribing and issuing medical recipes, avoiding and limiting incidents, side effects and polypharmacy or training the patients, limiting costs and evaluating new drugs. In the Netherlands there is a long tradition and different ways of collaboration between the family doctor and the pharmacist in order to meet the growing and especially changing medical needs of patients.","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43513843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Rosca, Societatea Română de Neurooftalmologie, M. Suliman, Societatea Română de Istoria Medicinei, Societatea Română de Istoria Farmaciei
{"title":"Fruits – essential foods","authors":"T. Rosca, Societatea Română de Neurooftalmologie, M. Suliman, Societatea Română de Istoria Medicinei, Societatea Română de Istoria Farmaciei","doi":"10.37897/RJPHP.2020.1.2","DOIUrl":"https://doi.org/10.37897/RJPHP.2020.1.2","url":null,"abstract":"","PeriodicalId":33513,"journal":{"name":"Practica Farmaceutica","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44676855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：